The Diabetes Report

Abstract

The number of people with diabetes has reached epidemic proportions, with the International Diabetes Federation currently stating that it is the fourth main cause of death in most developed countries. There are currently more than 194 million people with diabetes worldwide and by 2025 it is projected this number will rise to over 300 million

Understanding the key issues related to both Type I and Type II diabetes is vital for commerce and industry alike - and that is why The Diabetes Report is an essential part of your knowledge library

Every monthly issue reports the developments that matter!

Editorial

Type I Diabetes

• R&D Update
• Product News
• Agreement News

Type II Diabetes

• R&D Update
• Product News
• Agreement News General
• R&D Update
• Product News
• Agreement News

Related Complications

• R&D Update
• Product News
• Agreement News

Conference Listings

Every issue is extensively indexed by company and drug/product

The Diabetes Report is available in print, email and web formats. The web version of The Diabetes Report provides you with a daily updated news service, while the pdf & paper issues provide a monthly digest (12 issues per year)

Table of Contents

TYPE I DIABETES

• R&D Update
  • Study validates tight blood sugar control
  • Generex commences new Oral-lyn studies
  • Brain plays key role in diabetes therapy
  • Emory receives grant for advancing islet transplantation in Type I diabetes
  • Study finds more fractures and lower BMD in premenopausal females with Type I diabetes

TYPE II DIABETES

• R&D Update
  • Rosiglitazone added early to SU therapy effective in older Type II diabetes patients; combined with fenofibrate improves metabolic parameters; may improve memory in males
  • Generex' Metformin Gum shows similar PK profile to tablets
  • Hh protein shown to block fat production and produce more bone
  • CIDR to use Illumina whole-genome genotyping solutions to support study for Type II diabetes collaboration
  • deCODE discovers major genetic risk factor for Type II diabetes
  • PhytoMedical plans to accelerate development of cinnamon-derived compound for Type II diabetes
  • Extensive analysis confirms Lipitor' s safety
  • Positive results in Phase IIb dose-ranging study of MannKind' s Technosphere insulin in Type II diabetes
  • New evidence for increased CV mortality risk associated with SUs
  • Novartis to file Galvus in 2006
  • ConjuChem' s PC-DAC:Exendin-4 advancing into Phase I/II trial
  • Metaglidasen as effective as rosiglitazone and pioglitazone in preclinical study
  • Takeda' s SYR-322 in Phase III stage; ATL-962 enters Phase II studies
• Product News
  • GSK post-marketing reports warn of macular oedema with rosiglitazone products
  • Sanwa releases Seibule
  • Ajinomoto and Astellas file Fastic/Starsis sNDA for Type II diabetes
  • Ranbaxy launches Volix
• Agreement News
  • BI returns tesofensine rights to NeuroSearch

GENERAL

• R&D Update
  • UNSW produces new SC line
  • Generex granted US patent in connection with RapidMist device
  • Geron reports improved production method for hESC-derived islet cells
• Product News
  • Generex receives scheduling for Oral-lyn pre-NDS meeting
  • EC and FDA approve Exubera for treatment of Type I and II diabetes
• Agreement News
  • PS closes diabetes partnership
  • HGS receives milestone payment from GSK for GSK716155
  • Vitro and PhosphoSolutions enter SC proteomics collaboration
  • Pfizer acquires rights to Exubera from sanofi-aventis
  • ChemGenex and Merck enter diabetes agreement

RELATED COMPLICATIONS

• R&D Update
  • UVa scientists to search for new treatments for DNP
  • Ranirestat improves peripheral nerve function in DSP
  • King initiates Phase II trial evaluating MRE0094 in diabetic foot ulcers
  • Mosapride may improve appetite loss associated with diabetes
  • Corautus and CSEMC to study VEGF-2 for CLI
  • Molecular link between hyperglycaemia and retinopathy identified
  • Sangamo plans Phase II trial of SB-509 in DN
  • Discovery of glucagon secretion mechanism may lead to improved therapies for diabetics
  • Quigley' s SAB strongly supports next stage of development
  • Regranex gel confirmed as effective treatment for diabetic neuropathic foot ulcers

CONFERENCE LISTINGS

COMPANY INDEX

COMPOUND INDEX